Charlotte Piper with Ochsner Health

Charlotte Piper, Assistant Vice President of Ochsner Ventures, joins Panda Perspectives to explore how Ochsner Health is leveraging innovation, strategic investment, and deep collaboration to drive real change in healthcare. With a mission to create new value—financial and operational—for the health system, Charlotte shares how her team works across partnerships, internal ventures, and digital transformation initiatives to tackle some of the industry’s most complex challenges. Charlotte discusses Ochsner’s latest strategic plan, highlighting core priorities such as workforce experience, value-based care, digital enablement, and health equity. She emphasizes the growing importance of partnerships—both with peer health systems and early-stage companies—and the shift toward co-developing solutions rather than simply buying them.

Recent Episodes

As the field of cancer immunotherapy rapidly evolves, researchers are turning to next-generation in vitro technologies to replicate the complexities of the tumor microenvironment with unprecedented fidelity. Organoid platforms and ex vivo patient-derived tissue models are transforming how scientists approach preclinical testing, offering deeper mechanistic insights and better predictive power for therapeutic response. With immunotherapies…

In the rapidly advancing field of cancer immunotherapy, accurately modeling the tumor microenvironment (TME) has become essential to improving the predictive power of preclinical drug testing. As immune-modulating therapies surge forward, with over 4,000 immune modulators in development globally, scientists are refining assay technologies that maintain the complexity of patient-specific tumor biology. In vitro platforms…

As cancer immunotherapy continues to reshape treatment landscapes, fine-tuning T-cell responses has become a critical frontier. Recent advances in 3D organoid models and high-content imaging are enabling scientists to closely mimic patient-specific tumor environments—unlocking insights into how T cells behave, respond, and falter under immune checkpoint blockade. With over 4,000 immune modulators in clinical…